Hardman Johnston Global Advisors released its Q3 2025 investor letter, reporting a 5.02% return compared to MSCI AC World Net Index’s 7.62%. Top five holdings and underperformance details are available for download. Vertex Pharmaceuticals (VRTX) stock gained 8.76% in one month, closing at $462.90 per share with a $118.683 billion market cap on December 26, 2025.

Hardman Johnston Global Equity Strategy highlights Vertex Pharmaceuticals (VRTX) in its Q3 2025 investor letter, emphasizing its focus on cystic fibrosis therapies. Despite sector uncertainties, Vertex remains confident in its long-term outlook with a strong pipeline. The stock faced pressure due to chronic pain updates but has positive updates in other areas like kidney disease and gene-editing therapy.

Vertex Pharmaceuticals (VRTX) is held by 61 hedge fund portfolios, marking a 53% increase from the previous quarter. Q3 2025 revenue grew by 11% compared to Q3 2024. While Vertex shows investment potential, AI stocks are seen as offering greater upside potential and lower downside risk. For more insights, check out the free report on the best short-term AI stock.

For further insights on Vertex Pharmaceuticals (VRTX) and more investor letters, visit the hedge fund investor letters Q3 2025 page. Stay informed about the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money. This article is originally published at Insider Monkey.

Read more at Yahoo Finance: Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?